Researchers from several partner institutions of the German Center for Diabetes Research (DZD) have collaborated with international colleagues to develop a new approach for visualizing subtle tissue changes in the pancreas in type 2 diabetes. The results provide new insights into the development of type 2 diabetes. The study has now been published in Nature Communications.
Using machine learning, an electronic nose can “smell” early signs of ovarian cancer in the blood. The method is precise and, according to the LiU researchers behind the study, it could eventually be used to find many different cancers. The study is published in Advanced Intelligent Systems.
Researchers analysed data from two Alzheimer’s cohorts.
A protein lurking around in the blood can help with the accurate diagnosis of Alzheimer’s disease. In a recent study, researchers from Spain investigated how blood-based biomarkers, such as a protein called p-tau217, affect both the clinical diagnosis of Alzheimer’s and neurologists’ confidence in their diagnosis.
Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions. Using mice with human antibody genes, the research team developed new genetically human monoclonal antibodies that prevent two key antigens on the surface of the virus from binding to and entering human immune cells.
Medtronic continues to expand the growth opportunities for its hypertension-treating Symplicity Spyral renal denervation system.
LOUISVILLE, Ky., Feb. 19, 2026 /PRNewswire/ — Breath Diagnostics, Inc., a leader in breath-based molecular diagnostics powered by patented microreactor capture technology, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its OneBreath™ platform.
CHICAGO, Feb. 19, 2026 /PRNewswire/ — Sibel Health, a leader in medical-grade wearable sensor technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s recent Letter of Intent (LOI) into the Clinical Outcome Assessment (COA) Qualification Program under the Drug Development Tool (DDT) framework. The acceptance marks a significant milestone in advancing objective cough frequency measurement for adult patients with chronic refractory cough (CRC) using a novel Cough Monitoring sensor, the Aria sensor.
As aging populations and rising diabetes rates drive an increase in chronic wounds, more patients face the risk of amputations. UC Riverside researchers have developed an oxygen-delivering gel capable of healing injuries that might otherwise progress to limb lo
Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive form of the disease traditionally treated with surgical removal of the bladder. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that ultra-sensitive testing of tumor-derived DNA in blood and urine may help identify patients who can safely preserve their bladder without compromising cancer outcomes.